LISCure BioSciences Secures World’s First Approval for “Joint Health Probiotic” as Recognized Health Functional Ingredient

LISCure BioSciences (“LISCure”) announced that its proprietary joint health probiotic, JointWorks®, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient. This approval marks a historic milestone – JointWorks® is the world's first probiotic clinically proven to support joint healthand remains the onlyprobiotic ingredient approved by […]

All Around Polymer Unveils Data-Driven Framework for Nylon Compounding and Metal Replacement (Ardlon®)

New methodology accelerates validation cycles and boosts dimensional stability in polyamide applications With industries under pressure to replace metals with lighter, more durable materials, All Around Polymer (All Around Compounding), known for its Ardlon® brand, today unveiled a data-driven nylon compounding framework that drastically shortens validation cycles. This methodology positions the company at the forefront

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; “Renalys”) is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for Pediatric Nephrology (Head Office: Chiyoda-ku, Tokyo). The study is headed by Professor Kandai Nozu, Department of Pediatrics, Graduate School of Medicine, Kobe University. Renalys will provide

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

ACMBiolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM's proprietary polymersome platform through a strategic collaboration with the National Cancer Centre Singapore (NCCS). Preclinical experiments show that the ACM nanoparticle formulation fundamentally alters CpG's mechanism

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

ACMBiolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM's proprietary polymersome platform through a strategic collaboration with the National Cancer Centre Singapore (NCCS). Preclinical experiments show that the ACM nanoparticle formulation fundamentally alters CpG's mechanism

Xinhua Silk Road: Shanghai enhances int’l shipping center construction with transformative efforts

Shanghai is making steady progress in its drive to become an international shipping center, narrowing the gap with Singapore and London through transformative development efforts. https://mma.prnewswire.com/media/2802429/dcbcc29787b747318b9424064509e8cb.jpg After the 2025 North Bund Forum opened on Sunday and brought together shipping experts from around the world, the eastern Chinese metropolis is once again in the spotlight for

Oman Hosts the Oman Investment Forum 2025 in the United Kingdom

Reform Metrics and Global Outlook Underpin London Gathering LONDON, UK, OM / ACCESS Newswire / October 22, 2025 / The Sultanate of Oman, represented by the Ministry of Finance in cooperation with the Ministry of Foreign Affairs, held the Oman Investment Forum 2025 in London to deepen financial, investment, and economic cooperation between the two

Genflow Biosciences PLC Announces Second European Patent Application

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS

GBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East

(Helsinki:NOKIA),(Irish:IRSH),(LSE:0HAF),(Paris:NOKIA), Press ReleaseGBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East GBI's new network with Nokia will enhance its regional optical infrastructure with state-of-the-art technology that supports faster, more reliable access to digital services. The new scalable and low-latency network will offer 100G-400G services that boost network resilience

GBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East

GBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East GlobeNewswire October 22, 2025 Press ReleaseGBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East GBI's new network with Nokia will enhance its regional optical infrastructure with state-of-the-art technology that supports faster, more

Scroll to Top